HER2-ADC :

Jiawei Zhou1, Hanqing He1, Shuhang Wang1

  • 1Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Med (New York, N.Y.)
|March 9, 2024
PubMed
概括

针对HER2的抗体-药物结合体对具有特定HER2突变的非小细胞肺癌 (NSCLC) 具有前途. G776delinsVC突变表明反应率更高,为精准医学铺平了道路.